To include your compound in the COVID-19 Resource Center, submit it here.

Revimid: Phase I/II

In a U.S. Phase I/II trial, 16 of 25 (64%) evaluable

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE